Novo increases stake in SYNLAB

Novo increases stake in SYNLAB

Date
April 12, 2017

Munich / Hellerup, 12 April 2017 – SYNLAB Limited (“SYNLAB” or “the Group”), a European market leader for laboratory diagnostics, and Novo A/S (“Novo”), the holding company for the Novo Group and fully owned subsidiary of the Novo Nordisk Foundation, today jointly announce that Novo has agreed to increase its equity stake in the Group through a €250m subscription to new shares. Following the closing of the transaction which is scheduled to take place today, Novo will own a stake of approximately 20% of the equity of SYNLAB.

Novo Holdings uses cookies to ensure that we give you the best experience on our website. Read more